New peptides for imaging and treating aggressive breast cancer
Official title: Novel MUC1 Theranostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer
Funded at Stanford University · NIH-11010025 · Data updated 2026-11-12
This study is looking at new ways to treat triple-negative breast cancer by using special proteins that can deliver targeted radiation directly to the cancer cells, helping to make the treatment more effective and less harmful to healthy tissue.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $475,676 |
| NIH project number | 5R37CA278744-02 |
| Project ID | NIH-11010025 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who are seeking new treatment options.
✕Less likely to help
Patients with other subtypes of breast cancer or those who do not have MUC1 overexpression may not benefit from this research.
What this research studies
This research focuses on developing novel peptides that target MUC1, a protein overexpressed in triple-negative breast cancer (TNBC). The approach combines targeted radionuclide therapy (TRT) with these peptides to deliver localized radiation specifically to cancer cells while minimizing damage to normal tissues. By enhancing the effectiveness of treatment and reducing side effects, this research aims to improve outcomes for patients with TNBC. The study will involve creating and testing these peptides for their potential use in clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with triple-negative breast cancer.
How similar studies have gone: Previous research has shown promise in using targeted therapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Beinat, Corinne — Stanford University
- Study coordinator: Beinat, Corinne
Related research
Other NIH-funded projects on the same topics.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
A new peptide therapy to help treat metastatic triple-negative breast cancer
A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.